Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Gufic Biosciences Ltd (GUFICBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 509079 NSE: GUFICBIO Pharmaceuticals & Drugs | Small Cap | Gufic Biosciences Share Price

₹421.20 -9.85 (-2.29%)

As on 14-Aug'26 16:59

Gufic Biosciences Ltd (GUFICBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 509079 NSE: GUFICBIO Pharmaceuticals & Drugs | Small Cap | Gufic Biosciences Share Price

₹421.20 -9.85 (-2.29%)

As on 14-Aug'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹4,224 Cr.
Current Price
₹421.2
52-Week Low / High
₹268 / 448
TTM EPS
₹7.3
TTM Sales
₹974 Cr.
Book Value per Share
₹66.2
P/E Ratio
57.44
Higher than its 5-year historical median
Industry PE
53.5
Price to Book (P/B)
6.36
In line with its 5-year historical median
Price to Sales (P/S)
4.34
Higher than its 5-year historical median
EV/EBITDA
27.17
Higher than its 5-year historical median
Dividend Yield
0.02%
Profitability Efficiency
Return on Equity (ROE)
9.98%
Outperforms industry median
Return on Capital Employed (ROCE)
12.45%
Outperforms industry median
Return on Assets (ROA)
5.03%
Operating Profit Margin
16%
Net Profit Margin
6.71%
Gross Profit Margin
9.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
14.72%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
10.23%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-9.7%
Asset Quality
Promoter Holding
72.50%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹654 Cr.
Equity
₹10 Cr.
Face Value
₹1
All Time Low / High
₹0.17 / 501.10

Gufic Biosciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Gufic Biosciences Ltd a good quality company?
Gufic Biosciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Gufic Biosciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Gufic Biosciences Ltd vs industry peers?
Gufic Biosciences Ltd revenue CAGR is 14.04%, compared to the industry median CAGR of 5.75%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Gufic Biosciences Ltd?
Promoters hold 72.50% of the Gufic Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Gufic Biosciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 26.5% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gufic Biosciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ24.3%34.1%29.7%21%30.1%47.3%23.2%17.6%13.5%12.5%-
Value Creation
Index ⓘ		0.71.41.10.51.22.40.70.30.0-0.1-

Growth Parameters ⓘ
Sales ⓘ246306351379488779691807820940974
Sales YoY Gr.-24.5%14.8%8%28.7%59.8%-11.4%16.8%1.6%14.7%-
Adj EPS ⓘ1.11.92.82.44.59.88.48.77.16.37.3
YoY Gr.-74.8%43.3%-15.1%89%120.4%-14.2%3.4%-18.2%-12.1%-
BVPS (₹) ⓘ4.879.713.317.927.835.953.16066.266.2
Adj Net
Profit ⓘ		8.615.121.722.943.295.381.887.471.562.974
Cash Flow from Ops. ⓘ-4.1-4.85.247.187.3106-26.6-7.512344.2-
Debt/CF from Ops. ⓘ-13.7-16.518.82.50.60.6-11.7-42.52.58.7-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ16.1%14%10.8%14.7%
Adj EPS ⓘ21.2%7.1%-9.4%-12.1%
BVPSⓘ33.8%29.9%22.7%10.5%
Share Price 27% 16.3% 16.1% 18.4%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		24.23333.522.328.543.126.519.912.69.911.1
Op. Profit
Mgn % ⓘ		9.412.713.113.817.21919.918.616.91616.9
Net Profit
Mgn % ⓘ		3.54.96.268.912.211.810.88.76.77.6
Debt to
Equity ⓘ		1.51.51.30.90.30.20.90.60.50.6-
Working Cap
Days ⓘ		190201239254201136187213203204142
Cash Conv.
Cycle ⓘ		6786738447315591838950

Valuation of Gufic Biosciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales246306351379488779691807820940
Operating Expenses ⓘ + 223267305327404631556659683790
Manufacturing Costs32414751579387107125167
Material Costs107129161156226368295339310349
Employee Cost 41454759668687110127152
Other Costs ⓘ 42525060558486103121122
Operating Profit ⓘ 2339465284148135147136150
Operating Profit Margin (%) 9.3%12.7%13.1%13.8%17.2%19.0%19.5%18.3%16.6%16.0%
Other Income ⓘ + 1346433243
Exceptional Items ⓘ 0200000000
Interest ⓘ 6910141458172537
Depreciation ⓘ 44514161922172131
Profit Before Tax ⓘ 14303530581271071169485
Tax ⓘ 513137133127302422
Profit After Tax 9162223449680867063
PAT Margin (%) 3.7%5.4%6.3%6.0%9.1%12.3%11.5%10.7%8.5%6.7%
Adjusted EPS (₹)1.22.12.82.34.69.98.28.67.06.3
Dividend Payout Ratio (%)4.30%2.40%1.80%2.10%2.20%1%1.20%1.20%1.40%1.60%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 375475129173269348533601664
Share Capital ⓘ 88810101010101010
Reserves ⓘ 304668120164259338523591654
Debt +5477961135255302296285359
Long Term Debt7811203548191154130105
Short Term Debt47698593167112142154254
Minority Interest0000000000
Trade Payables447678117111141130166159199
Others Liabilities ⓘ 4028614883578098125119
Total Liabilities ⓘ 1752353104074195218601,0931,1701,342

Fixed Assets

Net Fixed Assets ⓘ +22232483100115160159506491
Gross Block263137115149180246246614630
Accumulated Depreciation48133249648787108139
CWIP ⓘ 02103113411703072222
Investments ⓘ 0000001233
Inventories63949412294116183200217324
Trade Receivables5281103107125152205330315297
Cash Equivalents 67816132747132874
Others Assets ⓘ 322871487472958179129
Total Assets ⓘ 1752353104074195218601,0931,1701,342
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + -4-554787106-27-712344
PBT ⓘ 14303530581271071169485
Adjustment ⓘ 10121325312330344465
Changes in Working Capital ⓘ -24-30-3428-11-135-1307-95
Tax Paid ⓘ -5-16-10-10-9-33-28-27-23-12
Cash Flow From Investing Activity ⓘ + -5-9-13-43-7-95-191-102-72-31
Capex -4-8-13-40-12-87-188-108-71-31
Net Investments 000000-1-1-1-0
Others ⓘ -1-10-36-7-27-00
Cash Flow From Financing Activity ⓘ + 7148-4-79-623482-3732
Net Proceeds from Shares ⓘ 000000010000
Net Proceeds from Borrowing ⓘ -11371212107-37-24-25
Interest Paid ⓘ -6-8-10-14-13-5-8-13-23-35
Dividend Paid ⓘ -0-0-0-0-0-1-1-1-1-1
Others ⓘ 1522153-77-12136331094
Net Cash Flow ⓘ -11-002517-271445
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)25.3136.0333.8922.1729.2243.3125.8419.5712.349.98
ROCE (%)24.2634.129.6521.0130.0547.2923.2317.5613.5112.45
Asset Turnover Ratio1.591.551.321.091.261.81.160.960.970.97
PAT to CFO Conversion(x)-0.44-0.310.232.041.981.1-0.34-0.081.760.7
Working Capital Days
Receivable Days75.9076.4093.209881.4059.4081.40103.90106.9091.70
Inventory Days79.4090.4095.40101.1076.3045.2068.1074.5069.2081.10
Payable Days163.70169.90173.90227.30184.30124.90167.50159.60191.40187.10

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gufic Biosciences Ltd FAQs

The current trading price of Gufic Biosciences on 14-Aug-2026 16:59 is ₹421.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Aug-2026 the market cap of Gufic Biosciences stood at ₹4,223.9 Cr

The latest P/E ratio of Gufic Biosciences as of 13-Aug-2026 is 57.44.

The latest P/B ratio of Gufic Biosciences as of 13-Aug-2026 is 6.36.

The 52-week high of Gufic Biosciences is ₹447.9 and the 52-week low is ₹267.5.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹974 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gufic Biosciences Ltd is a average quality company.

The key valuation ratios of Gufic Biosciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Gufic Biosciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

  • Pharmaceutical
  • Herbal
  • API / Bulk Drugs
  • Personal care
  • International

History and milestone

Past Initiatives

  • First Indian to produce Doxycycline Inj.
  • First Indian company to make Liquid Oxytetracycline Inj.
  • Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
  • First Company to launch Boswellia Serrata tablets
  • Pioneer in developing Kid tablet in India
  • Hived off Mox and Zole to Ranbaxy

2007-2009

  • Initiated contract manufacturing
  • Commenced international exports

2010-2015

  • Received patents for Anidulafungin and Tigecycline lyophilized inj.
  • Launched Criticare division

2016

  • Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
  • Launched Ferticare and Criticare Life divisions

2017-2019

  • Received patents for Rifabutin and Micafunginlyophilized inj.
  • Exported Vancomycin lyophilized Inj. to Germany
  • Manufacturing capacity ramped up to 31 million vials per annum
  • Launched Ferticare Life division

2020

  • Manufacturing Remdesivir for Hetero
  • Increased capacity to 48 million vials per annum

2022

  • Incorporated wholly owned subsidiary company namely ‘Gufic UK’
  • Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Address : The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: